Evoke Pharma Reports Third Quarter 2016 Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- Wall St futures muted as oil gains curb risk appetite after S&P record close
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Evoke Pharma (EVOK) Misses Q3 EPS by 3c
November 9, 2016 4:16 PM ESTEvoke Pharma (NASDAQ: EVOK) reported Q3 EPS of ($0.29), $0.03 worse than the analyst estimate of ($0.26).
Dave Gonyer, R.Ph., President and CEO, stated, The third quarter was a very active time for Evoke. After receiving results from our Phase 3 clinical trial of Gimoti for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women, we began extensive data analysis to better understand the outcome. We also completed a pre-New Drug Application... More
